Speciality European Pharma (SEP) has launched Regurin XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) in the UK.
Regurin XL is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with OAB.
The company said that Regurin XL provides significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects.
The company claims that a significantly higher number of patients in placebo controlled clinical trials achieved a reduction in urgency and wet days by week 12 with Regurin XL. Furthermore, Regurin XL has the benefit of not crossing the blood-brain barrier, or the blood eye barrier reducing the CNS side effects.
Geoff McMillan, CEO of SEP, said: “As a young company with a focus on Urology, the launch of Regurin XL is very exciting. Urinary incontinence is a very common and embarrassing problem and we believe that Regurin XL offers significant benefits for patients, their physicians and the health service as a whole.”